Zantac (ranitidine) is used to treat stomach and digestive problems, most commonly heartburn and gastric/intestinal ulcers. Zantac works by decreasing the amount of acid that your stomach makes. It belongs to a class of drugs known as H2 blockers.
Zantac is available by prescription and over-the-counter. Both brand name and generic versions are available.
On September 13, 2019, the FDA released a statement alerting patients and healthcare providers that NDMA (N-nitrosodimethylamine), a known carcinogen, was found in samples of Zantac. Over the next few months, various prescription and generic versions of Zantac were recalled from the U.S. market.
It has been determined that the NDMA found in Zantac is not a contamination. Rather, Zantac is defective in that the Zantac molecule is fundamentally unstable, and in certain environments, it breaks down into NDMA. Once NDMA is formed in the body, it is absorbed into the tissues.
On April 1, 2020, the FDA requested that all manufacturers immediately withdraw prescription and over-the-counter Zantac drugs due to excess levels of NDMA. The FDA also advised consumers taking Zantac to contact their healthcare provider to determine an alternative medication, as Zantac products will no longer be available for new or existing prescriptions or OTC use in the United States.
Zantac may put patients at risk for the following kinds of cancer:
• Stomach cancer
• Esophageal cancer
• Liver cancer
• Colorectal cancer
• Kidney cancer
• Bladder cancer
• Prostate cancer
• Pancreatic cancer
Neblett, Beard & Arsenault is investigating many cases on behalf of individuals who took Zantac and were thereafter diagnosed with cancer. If you, or a loved one, regularly used Zantac over an extended period of time and developed one of the cancers identified above, please contact us online or call our office directly at 318.588.6303 today for a free consultation.